Healthcare Japanese Community

AS ONE just put up a record year, but it signals a pause as it spends more on new facilities, logistics, and marketing to fuel the next leg of growth. The key question is whether these investments and a lift in demand for certain consumables can turn into stronger profits in the years ahead.Read more

JTEC’s optical business stays strong, with steadier customer demand helping losses shrink and deliveries improve. The next big question is whether new chip-making tools boosted by the rise of AI can turn early interest into real sales in the second half.Read more

Olympus is reshaping itself around customer needs and rolling out new tools for doctors, aiming to grow sales and improve profitability as demand for modern medical imaging rises. But its China business faces policy pressure and tougher competition, and heavy spending plus currency swings could slow progress.Read more

Mani faces growing pressure in China as tighter hospital buying rules and a push for local suppliers could squeeze what it can charge and what it earns. At the same time, bigger distributors in Europe and a tricky factory expansion mean execution matters more than ever—and the upside case depends on whether recent demand stays strong.Read more

Terumo is seeing stronger demand and better pricing power in key medical areas, helping it lift profits even as costs rise. The big question is whether that momentum holds as trade tensions, changing rules in China, and a thinner flow of new products start to bite.Read more

Olympus may be closer to a second act than the market expects, as newer digital tools and robotic endoscopy broaden what doctors can do with minimally invasive procedures. The upside depends on clearing key regulatory hurdles and keeping ahead of fast-moving rivals and new technology that could reshape how these procedures are done.Read more

Mani makes surgical and dental tools, and the story now hinges on whether China sales recover after a recall while the company pushes harder into new overseas markets. See what could lift profits through new products and factory upgrades—and what could derail it, from trade frictions to a money-losing overseas unit.Read more

PHC Holdings is pushing deeper into newer diabetes tools, digital pathology, and healthcare software as hospitals and patients move toward more at-home care and more digital records. The upside depends on new products and cost cleanups paying off, while weaker government funding, shrinking older product lines, and supply-chain shocks could hold results back.Read more

Sysmex may enjoy steady long-term demand as more people need routine blood and lab testing, but tougher pricing rules and cost controls in China could make growth harder than it looks. See what the company’s push into new regions, more direct selling, and internal efficiency efforts could mean—and what might trip them up.Read more